Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 47
Filtrar
1.
Semin Thorac Cardiovasc Surg ; 31(1): 32-37, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30102970

RESUMO

Medicare's Bundle Payment for Care Improvement (BPCI) Model 2 groups reimbursement for valve surgery into 90-day episodes of care, which include operative costs, inpatient stay, physician fees, postacute care, and readmissions up to 90 days postprocedure. We analyzed our BPCI patients' 90-day outcomes to understand the late financial risks and implications of the bundle payment system for valve patients. All BPCI valve patients from October 2013 (start of risk-sharing phase) to December 2015 were included. Readmissions were categorized as early (≤30 days) or late (31-90 days). Data were collected from institutional databases as well as Medicare claims. Analysis included 376 BPCI valve patients: 202 open and 174 transcatheter aortic valves (TAVR). TAVR patients were older (83.6 vs 73.8 years; P = 0.001) and had higher Society of Thoracic Surgery predicted risk (7.1% vs 2.8%; P = 0.001). Overall, 18.6% of patients (70/376) had one-or-more 90-day readmission, and total claim was on average 51% greater for these patients. Overall readmissions were more common among TAVR patients (22.4% (39/174) vs 15.3% (31/202), P = 0.052) as was late readmission. TAVR patients had significantly higher late readmission claims, and early readmission was predictive of late readmission for TAVR patients only (P = 0.04). Bundled claims for a 90-day episode of care are significantly increased in patients with readmissions. TAVR patients represent a high-risk group for late readmission, possibly a reflection of their chronic disease processes. Being able to identify patients at highest risk for 90-day readmission and the associated claims will be valuable as we enter into risk-bearing episodes of care agreements with Medicare.


Assuntos
Procedimentos Cirúrgicos Cardíacos/economia , Política de Saúde/economia , Doenças das Valvas Cardíacas/economia , Doenças das Valvas Cardíacas/cirurgia , Custos Hospitalares , Avaliação de Processos e Resultados em Cuidados de Saúde/economia , Pacotes de Assistência ao Paciente/economia , Readmissão do Paciente/economia , Idoso , Idoso de 80 Anos ou mais , Procedimentos Cirúrgicos Cardíacos/efeitos adversos , Procedimentos Cirúrgicos Cardíacos/legislação & jurisprudência , Procedimentos Cirúrgicos Cardíacos/mortalidade , Centers for Medicare and Medicaid Services, U.S./economia , Redução de Custos , Análise Custo-Benefício , Bases de Dados Factuais , Feminino , Política de Saúde/legislação & jurisprudência , Doenças das Valvas Cardíacas/diagnóstico , Doenças das Valvas Cardíacas/mortalidade , Custos Hospitalares/legislação & jurisprudência , Humanos , Masculino , Medicare/economia , Avaliação de Processos e Resultados em Cuidados de Saúde/legislação & jurisprudência , Readmissão do Paciente/legislação & jurisprudência , Formulação de Políticas , Mecanismo de Reembolso/economia , Medição de Risco , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento , Estados Unidos
2.
Ann Vasc Surg ; 52: 116-125, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-29783031

RESUMO

BACKGROUND: Patients with peripheral arterial disease often have high comorbidity burden that may complicate post-interventional course and drive increased health-care expenditures. Racial disparity had been observed in lower extremity revascularization (LER) patterns and outcomes. In 2014, Maryland adopted an all-payer rate-setting system to limit the rising hospitalization costs. This resulted in an aggregate payment system in which hospital compensation takes place as an overall per capita expenditure for hospital services. We sought to examine racial differences and other patient-level factors that might lead to discrepancies in LER hospital costs in the State of Maryland. METHODS: We used International Classification of Diseases, Ninth Revision codes to identify patients who underwent infrainguinal open bypass (open) and endovascular repair (endo) in the Maryland Health Services Cost Review Commission database (2009-2015). Multivariable generalized linear model regression analysis was conducted to report cost differences adjusting for patient-specific demographics, comorbidities, and insurance status. Logistic regression analysis was used to assess quality metrics: intensive care unit (ICU) admission, 30-day readmission, protracted length of stay (pLOS) (endo: pLOS >9, open: pLOS > 10 days) and in-hospital mortality. RESULTS: Among patients undergoing open, costs were higher for nonwhite patients (African-American [AA]: $6,092 [4,682-7,501], other: $3,324 [437-6,212]; both P ≤ 0.024), diabetics ($2,058 [837-3,279]; P < 0.001), and patients with Medicaid had an increased cost over Medicare patients by $4,325 (1,441-7,209). Critical limb ischemia (CLI) was associated with $5,254 (4,014-6,495) risk-adjusted cost increment. In addition, AA patients demonstrated higher risk-adjusted odds of ICU admission (adjusted odds ratio [aOR] [95% confidence interval {CI}]:1.65 [1.46-1.86]; P < 0.001) and pLOS (aOR [95% CI]: 1.56 [1.37-1.79]; P < 0.001) than their white counterparts. For patients undergoing endo, costs were higher for nonwhite patients (AA: $2,642 [1,574-3,711], other: $4,124 [2,091-6,157]; both P < 0.001). Patients with CLI and heart failure had increased costs after endo. AA patients were more likely to be readmitted or stayed longer after endo (1.16 [1.03-1.29], 1.34 [1.21-1.49]; both P < 0.010, respectively). The overall cost trend was rapidly increasing before all-payer rate policy implementation but it dramatically plateaued after 2014. CONCLUSIONS: This study showed that the all-payer rate-setting system has curbed the LER rising costs, but these costs remained disproportionally higher for disadvantaged populations such as AA and Medicaid communities. This underpins the existing racial disparity in LER. AA patients had higher LER costs, most likely driven by extended hospitalization and ICU admission. Efforts could be directed to evaluate the contributing socioeconomic factors, invest in primary prevention of comorbid conditions that had shown to be associated with prohibitive costs, and identify mechanisms to overcome the existing racial disparity in LER within the promising cost-saving payment system at the State of Maryland.


Assuntos
Procedimentos Endovasculares/economia , Disparidades em Assistência à Saúde/economia , Custos Hospitalares , Extremidade Inferior/irrigação sanguínea , Doença Arterial Periférica/economia , Doença Arterial Periférica/cirurgia , Avaliação de Processos em Cuidados de Saúde/economia , Procedimentos Cirúrgicos Vasculares/economia , Negro ou Afro-Americano , Idoso , Controle de Custos , Bases de Dados Factuais , Procedimentos Endovasculares/legislação & jurisprudência , Feminino , Disparidades em Assistência à Saúde/etnologia , Custos Hospitalares/legislação & jurisprudência , Humanos , Masculino , Maryland/epidemiologia , Medicaid/economia , Pessoa de Meia-Idade , Doença Arterial Periférica/diagnóstico , Doença Arterial Periférica/etnologia , Avaliação de Processos em Cuidados de Saúde/legislação & jurisprudência , Avaliação de Programas e Projetos de Saúde , Indicadores de Qualidade em Assistência à Saúde/economia , Fatores de Risco , Resultado do Tratamento , Estados Unidos , Procedimentos Cirúrgicos Vasculares/legislação & jurisprudência , População Branca
7.
J Med Pract Manage ; 28(4): 254-6, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23547503

RESUMO

As discussed in Part I of this article, hospital executives in Canada, Germany, and the United States manage their facilities' resources to maximize the incentives inherent in their respective reimbursement system and thereby increase their bottom line. It was also discussed that an additional supply of available hospitals, physicians, and other services will generate increased utilization. Part II discusses how the Patient Protection and Affordable Care Act of 2010 will eventually fail since it neither controls prices nor utilization (e.g., imaging, procedures, ambulatory surgery, discretionary spending). This article concludes with the discussion of the German multipayer approach with universal access and global budgets that might well be a model for U.S. healthcare in the future. Although the German healthcare system has a number of shortfalls, its paradigm could offer the most appropriate compromise when selecting the economic incentives to reduce the percentage of the U.S. gross domestic product expenditure for healthcare from 17.4% to roughly 12.0%.


Assuntos
Custos Hospitalares/organização & administração , Mecanismo de Reembolso/organização & administração , Reembolso de Incentivo/organização & administração , Orçamentos/legislação & jurisprudência , Orçamentos/organização & administração , Análise Custo-Benefício/economia , Análise Custo-Benefício/legislação & jurisprudência , Análise Custo-Benefício/organização & administração , Comparação Transcultural , Acessibilidade aos Serviços de Saúde/economia , Acessibilidade aos Serviços de Saúde/legislação & jurisprudência , Acessibilidade aos Serviços de Saúde/organização & administração , Custos Hospitalares/legislação & jurisprudência , Humanos , Corpo Clínico Hospitalar/organização & administração , Corpo Clínico Hospitalar/estatística & dados numéricos , Corpo Clínico Hospitalar/provisão & distribuição , National Health Insurance, United States/economia , National Health Insurance, United States/legislação & jurisprudência , Programas Nacionais de Saúde/economia , Programas Nacionais de Saúde/legislação & jurisprudência , Programas Nacionais de Saúde/organização & administração , Patient Protection and Affordable Care Act/economia , Patient Protection and Affordable Care Act/legislação & jurisprudência , Patient Protection and Affordable Care Act/organização & administração , Mecanismo de Reembolso/economia , Mecanismo de Reembolso/legislação & jurisprudência , Reembolso de Incentivo/economia , Reembolso de Incentivo/legislação & jurisprudência , Estados Unidos , Revisão da Utilização de Recursos de Saúde
8.
Chirurg ; 84(11): 978-86, 2013 Nov.
Artigo em Alemão | MEDLINE | ID: mdl-23512224

RESUMO

BACKGROUND: Due to the heterogeneity of severely injured patients (multiple trauma) it is difficult to assign them to homogeneic diagnosis-related groups (DRG). In recent years this has led to a systematic underfunding in the German reimbursement system (G-DRG) for cases of multiply injured patients. This project aimed to improve the reimbursement by modifying the case allocation algorithms of multiply injured patients within the G-DRG system. METHODS: A retrospective analysis of standardized G-DRG data according to §21 of the Hospital Reimbursement Act (§ 21 KHEntgG) including case-related cost data from 3,362 critically injured patients from 2007 and 2008 from 10 university hospitals and 7 large municipal hospitals was carried out. For 1,241 cases complementary detailed information was available from the trauma registry of the German Trauma Society to monitor the case allocation of multiply injured patients within the G-DRG system. Analysis of coding and grouping, performance of case allocation and the homogeneity of costs in the G-DRG versions 2008-2012 was carried out. RESULTS: The results showed systematic underfunding of trauma patients in the G-DRG version 2008 but adequate cost covering in the majority of cases with the G-DRG versions 2011 and 2012. Cost coverage was foundfor multiply injured patients from the clinical viewpoint who were identified as multiple trauma by the G-DRG system. Some of the overfunded trauma patients had high intensive care costs. Also there was underfunding for multiple injured patients not identified as such in the G-DRG system. CONCLUSIONS: Specific modifications of the G-DRG allocation structures could increase the appropriateness of reimbursement of multiply injured patients. Data-based analysis is an essential prerequisite for a constructive development of the G-DRG system and a necessary tool for the active participation of medical specialist societies.


Assuntos
Grupos Diagnósticos Relacionados/economia , Custos de Cuidados de Saúde/tendências , Traumatismo Múltiplo/economia , Traumatismo Múltiplo/cirurgia , Programas Nacionais de Saúde/economia , Cuidados Críticos/economia , Grupos Diagnósticos Relacionados/classificação , Previsões , Alemanha , Custos de Cuidados de Saúde/classificação , Custos Hospitalares/classificação , Custos Hospitalares/legislação & jurisprudência , Humanos , Traumatismo Múltiplo/classificação , Mecanismo de Reembolso/classificação , Mecanismo de Reembolso/economia , Mecanismo de Reembolso/legislação & jurisprudência
9.
Z Gerontol Geriatr ; 44(5): 323-8, 2011 Oct.
Artigo em Alemão | MEDLINE | ID: mdl-21976178

RESUMO

BACKGROUND: The importance of powers of attorney and legal guardians for patients in hospitals who are unable to make decisions for themselves is growing. Without an authorized person in these cases, treatment and discharge are more difficult. The goal of this study was to describe the problem from the point of view of an acute geriatric department and discuss the problems with respect to duration and expense of hospitalization. In addition, an attempt was undertaken to improve cooperation with the legal authorities in order to reduce the time required to process the request for the appointment of a legal guardian. MATERIALS AND METHOD: A total of 24 consecutive patients appointed a legal guardian during their hospitalization were compared with 25 patients after the intervention. RESULTS: Of all patients treated in 2008, 2.1% needed an application for an appointed legal guardian (4.6% in 2009). These patients were more seriously ill and treated longer in the hospital compared to all patients. The intervention reduced the length of stay on average by 2.8 days. Independent risk factors for longer treatment were more seriously ill patients and later submission of the application after admittance to the hospital. For patients above the maximum length of stay, the move to a nursing home and the need of a professional legal guardian prolonged significantly the hospital treatment compared to those below the maximum length of stay. CONCLUSION: The data demonstrate that the German DRG system does not sufficiently consider the difficult management caused by patients without the ability to give consent to treatment and without a valid power of attorney. The time required until a professional legal guardian is appointed is too long for patients in a hospital. The necessity of a power of attorney has to be promoted more intensely to the public. Currently, the only two ways to minimize the problem is to identify the patients without, but needing a power of attorney as quickly as possible and to remain in close contact with the legal authorities.


Assuntos
Serviços de Saúde para Idosos/legislação & jurisprudência , Tutores Legais/legislação & jurisprudência , Tempo de Internação/legislação & jurisprudência , Testamentos Quanto à Vida/legislação & jurisprudência , Competência Mental/legislação & jurisprudência , Programas Nacionais de Saúde/legislação & jurisprudência , Idoso , Idoso de 80 Anos ou mais , Grupos Diagnósticos Relacionados/economia , Grupos Diagnósticos Relacionados/legislação & jurisprudência , Prova Pericial/economia , Prova Pericial/legislação & jurisprudência , Feminino , Alemanha , Serviços de Saúde para Idosos/economia , Instituição de Longa Permanência para Idosos/economia , Instituição de Longa Permanência para Idosos/legislação & jurisprudência , Custos Hospitalares/legislação & jurisprudência , Humanos , Tempo de Internação/economia , Testamentos Quanto à Vida/economia , Masculino , Programas Nacionais de Saúde/economia , Casas de Saúde/economia , Casas de Saúde/legislação & jurisprudência , Alta do Paciente/economia , Alta do Paciente/legislação & jurisprudência , Transferência de Pacientes/economia , Transferência de Pacientes/legislação & jurisprudência , Estudos Prospectivos , Mecanismo de Reembolso/economia , Mecanismo de Reembolso/legislação & jurisprudência
11.
BMC Health Serv Res ; 11: 150, 2011 Jun 24.
Artigo em Inglês | MEDLINE | ID: mdl-21702947

RESUMO

BACKGROUND: Accounting for 36% of public spending on health care in Canada, hospitals are a major target for cost reductions through various efficiency initiatives. Some provinces are considering payment reform as a vehicle to achieve this goal. With few exceptions, Canadian provinces have generally relied on global and line-item budgets to contain hospital costs. There is growing interest amongst policy-makers for using activity based funding (ABF) as means of creating financial incentives for hospitals to increase the 'volume' of care, reduce cost, discourage unnecessary activity, and encourage competition. British Columbia (B.C.) is the first province in Canada to implement ABF for partial reimbursement of acute hospitalization. To date, there have been no formal examinations of the effects of ABF policies in Canada. This study proposal addresses two research questions designed to determine whether ABF policies affect health system costs, access and hospital quality. The first question examines the impact of the hospital funding policy change on internal hospital activity based on expenditures and quality. The second question examines the impact of the change on non-hospital care, including readmission rates, amount of home care provided, and physician expenditures. METHODS/DESIGN: A longitudinal study design will be used, incorporating comprehensive population-based datasets of all B.C. residents; hospital, continuing care and physician services datasets will also be used. Data will be linked across sources using anonymized linking variables. Analytic datasets will be created for the period between 2005/2006 and 2012/2013. DISCUSSION: With Canadian hospitals unaccustomed to detailed scrutiny of what services are provided, to whom, and with what results, the move toward ABF is significant. This proposed study will provide evidence on the impacts of ABF, including changes in the type, volume, cost, and quality of services provided. Policy- and decision-makers in B.C. and elsewhere in Canada will be able to use this evidence as a basis for policy adaptations and modifications. The significance of this proposed study derives from the fact that the change in hospital funding policy has the potential to affect health system costs, residents' access to care and care quality.


Assuntos
Regulamentação Governamental , Custos Hospitalares/legislação & jurisprudência , Mecanismo de Reembolso/legislação & jurisprudência , Colúmbia Britânica , Controle de Custos/legislação & jurisprudência , Feminino , Acessibilidade aos Serviços de Saúde , Humanos , Estudos Longitudinais , Masculino , Programas Nacionais de Saúde
14.
Z Psychosom Med Psychother ; 56(1): 86-105, 2010.
Artigo em Alemão | MEDLINE | ID: mdl-20229494
15.
Urologe A ; 47(9): 1239-44, 2008 Sep.
Artigo em Alemão | MEDLINE | ID: mdl-18679653

RESUMO

New diagnostic or therapeutic options (NDTOs) are remunerated separately in the German DRG system. The Institute for Remuneration in Hospitals decides which proposed NDTOs are accepted for separate remuneration for 1 year. With this acceptance, hospitals can enter negotiations with insurance companies for an individual price of the NDTO. Because there are no general recommendations for these negotiations, we present a scheme for how to calculate an NDTO, based on the example of the NDTO for transurethral resection of bladder tumors using photodynamic diagnostic with hexaminolevulinic acid.


Assuntos
Ácido Aminolevulínico/análogos & derivados , Biópsia/economia , Cistoscopia/economia , Grupos Diagnósticos Relacionados/economia , Custos Hospitalares/legislação & jurisprudência , Terapia a Laser/economia , Lasers de Estado Sólido/uso terapêutico , Programas Nacionais de Saúde/economia , Mecanismo de Reembolso/economia , Tecnologia de Alto Custo/economia , Neoplasias da Bexiga Urinária/economia , Ácido Aminolevulínico/economia , Orçamentos/organização & administração , Carcinoma de Células de Transição/diagnóstico , Carcinoma de Células de Transição/economia , Carcinoma de Células de Transição/patologia , Carcinoma de Células de Transição/cirurgia , Análise Custo-Benefício/legislação & jurisprudência , Grupos Diagnósticos Relacionados/legislação & jurisprudência , Alemanha , Humanos , Programas Nacionais de Saúde/legislação & jurisprudência , Negociação , Estadiamento de Neoplasias , Mecanismo de Reembolso/legislação & jurisprudência , Tecnologia de Alto Custo/legislação & jurisprudência , Estudos de Tempo e Movimento , Neoplasias da Bexiga Urinária/diagnóstico , Neoplasias da Bexiga Urinária/patologia , Neoplasias da Bexiga Urinária/cirurgia
19.
Med Law ; 25(2): 267-71, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16929805

RESUMO

This paper examines the outcomes of the latest ruling from the European Court of Justice on receiving hospital care abroad. It has been argued that the Court has extended the patient's right to cross border care towards third countries at the cost of member states' autonomy on organising their social health system.


Assuntos
Custos Hospitalares/legislação & jurisprudência , Mecanismo de Reembolso/legislação & jurisprudência , Feminino , Alemanha , Humanos , Neoplasias Nasais/cirurgia , Transferência de Pacientes/legislação & jurisprudência , Espanha , Suíça
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA